Please join us for this on-demand webinar, at which you will learn how protein biomarker data using Olink Explore is playing a vital role in multiomic studies aimed at better understanding and treating COVID-19.
Associate Professor Niklas Björkström (Karolinska University Hospital) will describe how a systems biology approach incorporating multiple omics technologies is being used to comprehensively map the host immune system response to SARS-Cov-2 infection and subsequent disease.
Dr. Fridtjof Lund-Johansen (Oslo University Hospital) will describe the work that his group is doing to investigate the potential side-effects of COVID-19 vaccination.
Niklas Björkström
Associate Professor, Karolinska Institute, Stockholm, Sweden
“The Karolinska COVID-19 Immune Atlas”
Fridtjof Lund-Johansen MD
Oslo University Hospital, Oslo, Norway
“Serum proteomics in patients with vaccine-induced thrombosis and thrombocytopenia"
Professor Hans-Gustaf Ljunggren
Karolinska Institute, Stockholm, Sweden
Panelist Q&A session
Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways.
Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base.